top of page
what-is-cell-therapy.jpg

Cell & Gene Therapy:

The future of Cancer Treatment - Targeting Complete Cure

ABOUT US

We are dedicated to realizing the potential of natural killer (NK) cells for the treatment of cancer. Our proprietary technology is designed to harness the power of these important pathogen-fighting immune cells and is uniquely capable of enhancing their ability to search and destroy tumor cells.

newimage.jpeg

Off the shelf Allogenic Platform

Recognising the potential of cell therapy by enhancing a key type of immune cell, Natural Killer (NK) cells, with new properties to create transformative cancer treatments for more patients. Using synthetic biology and non-viral cell engineering, it is possible to develop a highly potent allogeneic, off-the-shelf chimeric antigen receptor (CAR)-NK cell therapies capable of treating challenging cancers, including solid tumors, by combining new functional attributes with the inherent cancer-fighting properties of NK cells.

OUR

VISION

To bring curative allogenic cell therapies to India & ROW at the same time as the US & Europe

Science Lab
Microscope

OUR

MISSION

To ensure early, affordable and quality access to curative cell therapies to patients in India
& ROW

HARNSESSING THE POWER OF NK-CELL FOR CANCER TREATMENT

Off the shelf

Allogenic Platform

Recognising the potential of cell therapy by enhancing a key type of immune cell, Natural Killer (NK) cells, with new properties to create transformative cancer treatments for more patients. Using synthetic biology and non-viral cell engineering, it is possible to develop a highly potent allogeneic, off-the-shelf chimeric antigen receptor (CAR)-NK cell therapies capable of treating challenging cancers, including solid tumors, by combining new functional attributes with the inherent cancer-fighting properties of NK cells.

newimage.jpeg

OUR VIRAL VECTOR PLATFORM

Platform to support broad range of virus types. GMP production services using both transient transfection and stable packaging cell-line-based processes.Support production of vectors with either adherent or suspension-based platforms.

-profilepic.png

Director & Co-founder

Dr. (Maj) Dinesh Kundu

(MBBS, MBA)

Dr. Dinesh Kundu - New.png
  • 15 years of experience in Biotech & Healthcare Delivery.

  • MBBS, MBA (ISB & LBS)

  • Core expertise – Business Strategy & Clinical Strategy

  • Global Clinical Trials and launch planning of E.Coli

Mitul Agrawal.png

Director & Co-founder

Mitul Agarwal

B. Pharma, MBA

Dr. Mitul Agrawal - New.png
  • 20 years of experience in Biotech & Plasma Baxter, Fresenius, Intas

  • Core expertise – Business Development, Sales, in-licensing

  • Global & India new product launches Launch & pricing strategies

dr.renu.png

Director & Co-founder

Dr. Renu Kundu

MDS, PhD

Dr. Renu Kundu - New.png
  • Experience of devising Regulatory Strategy for Filings in DCGI and ROW markets.

  • Coordination with CROs for the pre-clinical and clinical trials.

Dr. Narinder Mehra.png

Director & Co-founder

Dr. Narinder Mehra

PhD, Post Doc Immunogenetics

Dr. Narendra Mehra - New.png
  • Pioneer of Transplant Immunology and Immunogenetics in India.

  • India’s top Science Award winner – Bhatnagar Prize & more than 100 awards.

  • Founding member and fellow of  leading global Societies.

  • Advisor to Indian FDA and Govt on establishing regulations.

Leadership

bottom of page